Cargando…
Safety Profile of a Virus-Like Particle-Based Vaccine Targeting Self-Protein Interleukin-5 in Horses
Background: Insect bite hypersensitivity (IBH) is an eosinophilic allergic dermatitis of horses caused by type I/IVb reactions against mainly Culicoides bites. The vaccination of IBH-affected horses with equine IL-5 coupled to the Cucumber mosaic virus-like particle (eIL-5-CuMV(TT)) induces IL-5-spe...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7349629/ https://www.ncbi.nlm.nih.gov/pubmed/32397549 http://dx.doi.org/10.3390/vaccines8020213 |
_version_ | 1783557099002789888 |
---|---|
author | Jonsdottir, Sigridur Fettelschoss, Victoria Olomski, Florian Talker, Stephanie C. Mirkovitch, Jelena Rhiner, Tanya Birkmann, Katharina Thoms, Franziska Wagner, Bettina Bachmann, Martin F. Kündig, Thomas M. Marti, Eliane Fettelschoss-Gabriel, Antonia |
author_facet | Jonsdottir, Sigridur Fettelschoss, Victoria Olomski, Florian Talker, Stephanie C. Mirkovitch, Jelena Rhiner, Tanya Birkmann, Katharina Thoms, Franziska Wagner, Bettina Bachmann, Martin F. Kündig, Thomas M. Marti, Eliane Fettelschoss-Gabriel, Antonia |
author_sort | Jonsdottir, Sigridur |
collection | PubMed |
description | Background: Insect bite hypersensitivity (IBH) is an eosinophilic allergic dermatitis of horses caused by type I/IVb reactions against mainly Culicoides bites. The vaccination of IBH-affected horses with equine IL-5 coupled to the Cucumber mosaic virus-like particle (eIL-5-CuMV(TT)) induces IL-5-specific auto-antibodies, resulting in a significant reduction in eosinophil levels in blood and clinical signs. Objective: the preclinical and clinical safety of the eIL-5-CuMV(TT) vaccine. Methods: The B cell responses were assessed by longitudinal measurement of IL-5- and CuMV(TT)-specific IgG in the serum and plasma of vaccinated and unvaccinated horses. Further, peripheral blood mononuclear cells (PBMCs) from the same horses were re-stimulated in vitro for the proliferation and IFN-γ production of specific T cells. In addition, we evaluated longitudinal kidney and liver parameters and the general blood status. An endogenous protein challenge was performed in murine IL-5-vaccinated mice. Results: The vaccine was well tolerated as assessed by serum and cellular biomarkers and also induced reversible and neutralizing antibody titers in horses and mice. Endogenous IL-5 stimulation was unable to re-induce anti-IL-5 production. The CD4(+) T cells of vaccinated horses produced significantly more IFN-γ and showed a stronger proliferation following stimulation with CuMV(TT) as compared to the unvaccinated controls. Re-stimulation using E. coli-derived proteins induced low levels of IFNγ(+)CD4(+) cells in vaccinated horses; however, no IFN-γ and proliferation were induced following the HEK-eIL-5 re-stimulation. Conclusions: Vaccination using eIL-5-CuMV(TT) induces a strong B-cell as well as CuMV(TT)-specific T cell response without the induction of IL-5-specific T cell responses. Hence, B-cell unresponsiveness against self-IL-5 can be bypassed by inducing CuMV(TT) carrier-specific T cells, making the vaccine a safe therapeutic option for IBH-affected horses. |
format | Online Article Text |
id | pubmed-7349629 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-73496292020-07-14 Safety Profile of a Virus-Like Particle-Based Vaccine Targeting Self-Protein Interleukin-5 in Horses Jonsdottir, Sigridur Fettelschoss, Victoria Olomski, Florian Talker, Stephanie C. Mirkovitch, Jelena Rhiner, Tanya Birkmann, Katharina Thoms, Franziska Wagner, Bettina Bachmann, Martin F. Kündig, Thomas M. Marti, Eliane Fettelschoss-Gabriel, Antonia Vaccines (Basel) Article Background: Insect bite hypersensitivity (IBH) is an eosinophilic allergic dermatitis of horses caused by type I/IVb reactions against mainly Culicoides bites. The vaccination of IBH-affected horses with equine IL-5 coupled to the Cucumber mosaic virus-like particle (eIL-5-CuMV(TT)) induces IL-5-specific auto-antibodies, resulting in a significant reduction in eosinophil levels in blood and clinical signs. Objective: the preclinical and clinical safety of the eIL-5-CuMV(TT) vaccine. Methods: The B cell responses were assessed by longitudinal measurement of IL-5- and CuMV(TT)-specific IgG in the serum and plasma of vaccinated and unvaccinated horses. Further, peripheral blood mononuclear cells (PBMCs) from the same horses were re-stimulated in vitro for the proliferation and IFN-γ production of specific T cells. In addition, we evaluated longitudinal kidney and liver parameters and the general blood status. An endogenous protein challenge was performed in murine IL-5-vaccinated mice. Results: The vaccine was well tolerated as assessed by serum and cellular biomarkers and also induced reversible and neutralizing antibody titers in horses and mice. Endogenous IL-5 stimulation was unable to re-induce anti-IL-5 production. The CD4(+) T cells of vaccinated horses produced significantly more IFN-γ and showed a stronger proliferation following stimulation with CuMV(TT) as compared to the unvaccinated controls. Re-stimulation using E. coli-derived proteins induced low levels of IFNγ(+)CD4(+) cells in vaccinated horses; however, no IFN-γ and proliferation were induced following the HEK-eIL-5 re-stimulation. Conclusions: Vaccination using eIL-5-CuMV(TT) induces a strong B-cell as well as CuMV(TT)-specific T cell response without the induction of IL-5-specific T cell responses. Hence, B-cell unresponsiveness against self-IL-5 can be bypassed by inducing CuMV(TT) carrier-specific T cells, making the vaccine a safe therapeutic option for IBH-affected horses. MDPI 2020-05-09 /pmc/articles/PMC7349629/ /pubmed/32397549 http://dx.doi.org/10.3390/vaccines8020213 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Jonsdottir, Sigridur Fettelschoss, Victoria Olomski, Florian Talker, Stephanie C. Mirkovitch, Jelena Rhiner, Tanya Birkmann, Katharina Thoms, Franziska Wagner, Bettina Bachmann, Martin F. Kündig, Thomas M. Marti, Eliane Fettelschoss-Gabriel, Antonia Safety Profile of a Virus-Like Particle-Based Vaccine Targeting Self-Protein Interleukin-5 in Horses |
title | Safety Profile of a Virus-Like Particle-Based Vaccine Targeting Self-Protein Interleukin-5 in Horses |
title_full | Safety Profile of a Virus-Like Particle-Based Vaccine Targeting Self-Protein Interleukin-5 in Horses |
title_fullStr | Safety Profile of a Virus-Like Particle-Based Vaccine Targeting Self-Protein Interleukin-5 in Horses |
title_full_unstemmed | Safety Profile of a Virus-Like Particle-Based Vaccine Targeting Self-Protein Interleukin-5 in Horses |
title_short | Safety Profile of a Virus-Like Particle-Based Vaccine Targeting Self-Protein Interleukin-5 in Horses |
title_sort | safety profile of a virus-like particle-based vaccine targeting self-protein interleukin-5 in horses |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7349629/ https://www.ncbi.nlm.nih.gov/pubmed/32397549 http://dx.doi.org/10.3390/vaccines8020213 |
work_keys_str_mv | AT jonsdottirsigridur safetyprofileofaviruslikeparticlebasedvaccinetargetingselfproteininterleukin5inhorses AT fettelschossvictoria safetyprofileofaviruslikeparticlebasedvaccinetargetingselfproteininterleukin5inhorses AT olomskiflorian safetyprofileofaviruslikeparticlebasedvaccinetargetingselfproteininterleukin5inhorses AT talkerstephaniec safetyprofileofaviruslikeparticlebasedvaccinetargetingselfproteininterleukin5inhorses AT mirkovitchjelena safetyprofileofaviruslikeparticlebasedvaccinetargetingselfproteininterleukin5inhorses AT rhinertanya safetyprofileofaviruslikeparticlebasedvaccinetargetingselfproteininterleukin5inhorses AT birkmannkatharina safetyprofileofaviruslikeparticlebasedvaccinetargetingselfproteininterleukin5inhorses AT thomsfranziska safetyprofileofaviruslikeparticlebasedvaccinetargetingselfproteininterleukin5inhorses AT wagnerbettina safetyprofileofaviruslikeparticlebasedvaccinetargetingselfproteininterleukin5inhorses AT bachmannmartinf safetyprofileofaviruslikeparticlebasedvaccinetargetingselfproteininterleukin5inhorses AT kundigthomasm safetyprofileofaviruslikeparticlebasedvaccinetargetingselfproteininterleukin5inhorses AT martieliane safetyprofileofaviruslikeparticlebasedvaccinetargetingselfproteininterleukin5inhorses AT fettelschossgabrielantonia safetyprofileofaviruslikeparticlebasedvaccinetargetingselfproteininterleukin5inhorses |